Ricevi le ultime notizie sulle azioni Pluri con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PLUR

Ultime notizie per

Pluri

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Pluri Inc

Plurilock Security Inc

PLURAL INDUSTRY HLDG GRP by Plural Industry Holding Group Co. Limited

Plural Industry Holding Group Co Ltd

Pluribus Technologies Corp

Plurilock Security Inc Ordinary Shares

Press Releases

Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

General

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom

News

Legal

Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

Penny Stocks

Small Cap

DarioHealth Announces CFO Transition

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

ADIA

BCLI

BNRG

DRIO

FATE

PLUR

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Annovis Bio

AlphaTON Capital

BioAtla

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Evaxion

Generation Bio

IO Biotech

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kezar Life Sciences

LAVA Therapeutics

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Senti Biosciences

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

Comments

Pluri Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO